Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Ab-interno canaloplasty for the treatment of glaucoma: a case series study

Poster Details

First Author: N.Koerber GERMANY

Co Author(s):    S. Ondrejka                    

Abstract Details


To evaluate the efficacy and safety of ABiC in patients with primary open-angle glaucoma (POAG) in combined surgery.


Augencentrum Koeln, Germany


Patients (mean age, 76 years; range, 66-83 years) underwent ABiC using the iTrack™ 250-micron microcatheter (Ellex Medical Lasers Pty Ltd, Adelaide, Australia) to circumferentially viscodilate and intubate Schlemm’s canal without placement of a tensioning suture. The primary endpoints were mean intraocular pressure (IOP) and mean number of glaucoma medications at 1, 3, 6, 9 and 12 and 24 months postoperative.


Twenty five eyes of 23 patients (mean age, 77,2± 5.87 years; 12 male: 11 female) were assessed. Mean IOP fell from 18.8 ± 3,8 mmHg preoperatively to 14.9 ± 3,25 mm Hg (n=25), 14,39 ± 2.3 (n=18), 14.66 ± 2.65 mm Hg (n=18), 14,09 ± 2.6 (n=15), 15,6 ± 2.0 (n=16) at 1, 6, 12,18 and 24 months postoperatively, respectively. Mean number of medications fell from 2,0 preoperatively to 0.6 at the last follow-up visit (N=25). Only 1 complication was reported: limited descemetolysis by viscoelastic during dilatation of Schlemm`s canal. No device-related adverse events were reported.


The study findings suggest that ABiC effectively lowers IOP and medication dependency. ABiC was straightforward to perform in this group of patients, with minimal complications and no reported adverse events. Larger-scale studies with longer follow up periods are required to further validate the observations made in the current study and corroborate the clinical efficacy of this minimally-invasive glaucoma procedure.

Financial Disclosure:


Back to Poster listing